Similarity in effectiveness and cardiac safety has also been demonstrated in a real-world evidence (RWE) study comparing biosimilar Herzuma to Herceptin for the treatment of HER2+ early breast cancer [12]. The gene discussed is ERBB2; the disease is breast cancer.